Nezavist

Nezavist
Clinical data
Other namesDCUK-OEt; DCUKA ethyl ester; DCUK ethyl carboxylate
Routes of
administration		Oral
Drug classPeripherally selective GABAA receptor positive allosteric modulator
Identifiers
  • ethyl 5,7-dichloro-4-(diphenylcarbamoylamino)quinoline-2-carboxylate
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC25H19Cl2N3O3
Molar mass480.35 g·mol−1
3D model (JSmol)
  • CCOC(=O)C1=NC2=C(C(=C1)NC(=O)N(C3=CC=CC=C3)C4=CC=CC=C4)C(=CC(=C2)Cl)Cl
  • InChI=1S/C25H19Cl2N3O3/c1-2-33-24(31)22-15-21(23-19(27)13-16(26)14-20(23)28-22)29-25(32)30(17-9-5-3-6-10-17)18-11-7-4-8-12-18/h3-15H,2H2,1H3,(H,28,29,32)
  • Key:UHTVXLVKFPJKMP-UHFFFAOYSA-N

Nezavist, also known as DCUK-OEt, is a peripherally selective GABAA receptor positive allosteric modulator which is under development for the treatment of alcoholism and depressive disorders. It is taken orally. The drug is a positive allosteric modulator (PAM) specifically of the etomidate allosteric site of the GABAA receptor. As it does not cross the blood–brain barrier, Nezavist is peripherally selective and does not directly produce central nervous system effects. Nonetheless, the drug has been found to reduce alcohol self-administration in rodents, perhaps via intestinal stimulation of the vagus nerve. Nezavist is under development by Lohocla Research. As of October 2025, it is in phase 1 clinical trials for alcoholism and the preclinical research stage of development for depressive disorders.

See also

References

  1. 1 2 3 4 5 "DCUK OEt". AdisInsight. 10 October 2025. Retrieved 18 May 2026.
  2. 1 2 3 "Delving into the Latest Updates on Nezavist with Synapse". Synapse. 8 May 2025. Retrieved 18 May 2026.
  3. 1 2 Hoffman PL, de Guglielmo G, Vengeliene V, Kunze W, Lebonville CL, Swinny JD, et al. (March 2026). "Engaging Gut-to-Brain Signalling to Treat Alcohol Use Disorder". Addiction Biology. 31 (3) e70144. doi:10.1111/adb.70144. PMC 13093268. PMID 41879717.
  4. 1 2 3 Simeone X, Khom S, Doppler AM, Seidel T, Scholze P, Tabakoff B, et al. (January 2026). "Nezavist (DCUK-OEt) and aminoquinoline analogues interact with the etomidate site and display a complex mode of modulatory action of the GABAA receptor". European Journal of Pharmacology. 1012 178464. doi:10.1016/j.ejphar.2025.178464. PMID 41419089.